SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health safety and infectious disease markets in the United States. The company is headquartered in New York, New York.
| Revenue (TTM) | $94.58M |
| Gross Profit (TTM) | $44.91M |
| EBITDA | $24.26M |
| Operating Margin | -250.40% |
| Return on Equity | 11.20% |
| Return on Assets | 6.39% |
| Revenue/Share (TTM) | $1.32 |
| Book Value | $2.78 |
| Price-to-Book | 1.63 |
| Price-to-Sales (TTM) | 3.44 |
| EV/Revenue | 1.788 |
| EV/EBITDA | 6.97 |
| Quarterly Earnings Growth (YoY) | 1802.00% |
| Quarterly Revenue Growth (YoY) | -95.30% |
| Shares Outstanding | $71.72M |
| Float | $40.51M |
| % Insiders | 42.66% |
| % Institutions | 51.88% |
Volatility is currently contracting